Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Formulation and Evaluation of Transdermal Patch Containing Sibutramine

  • Published : 2010.02.20
Download PDF
⟨ Previous Next ⟩

Abstract

Sibutramine is a serotonin-norepinephrine reuptake inhibitor indicated for the management of obesity in conjunction with a reduced calorie diet. The oral administration of sibutramine is followed by its dose-related side effects. In this study, sibutramine was formulated into drug in adhesive (DIA) patches in an attempt to overcome these problems. The effects of different formulation variables including pressure-sensitive adhesive (PSA), loading amount of drug, thickness of matrix and enhancer on the skin permeation of the drug were evaluated using excised hairless mouse skin. In the acrylic adhesive with carboxyl functional group, low release of sibutramine was observed due to the strong interaction between carboxyl group of adhesive and amine group of sibutramine. The acrylic adhesive without functional group provided good adhesion force and allowed high drug loading. Changing drug load as well as thickness of the matrix was found to alter permeation rate. $Crovol^{(R)}$ PK40 and $Crovol^{(R)}$ A40, were found to be effective enhancers for sibutramine. The optimized patch contained 20% sibutramine, and 5% $Crovol^{(R)}$ A40 as permeation enhancer, in $80\;{\mu}m$ thick Duro-$Tak^{(R)}$ 87-9301 matrix.

Keywords

References

  1. D.J. Goldsetin, Beneficial health effects of modest weight loss. Int. J. Obesity., 16, 397-415 (1992).
  2. L.B. Cannistra, S.M. Davis and A.G. Bauman, Valvular heart disease associated with desfenfluramine, (letter). N. Engl. J. Med., 337, 636 (1997). https://doi.org/10.1056/NEJM199708283370912
  3. W.N. Kernan, C.M. Viscoli, L.M. Brass, J.P. Broderick, T.Brott, E. Feldmann, L.B. Morgenstern, J.L. Wilterdink and R.I.Horwitz, Phenylpropanolamine and the risk of hemorrhagicstroke. N. Engl. J. Med., 343, 1826-1832 (2000). https://doi.org/10.1056/NEJM200012213432501
  4. L. Sjostrom, J-P. Despres and A. Golay, Weight loss in overweight/obese dyslipidemia subjects treated with rimonbant: the RIO-Lipids trial. Int. J. Obesity., 28(s28) (2004).
  5. C.A. Luque and J.A. Rey, The discovery status of sibutramine as an antiobesity drug. Eur. J. of Pharmacol., 440, 119-128(2002). https://doi.org/10.1016/S0014-2999(02)01423-1
  6. R. Padwal, S.K. Li and D.C.W. Lau, Long term pharmacotherapy for overweight and obesity: A systemic review and meta analysis of randomized control trials. Int. J. Obesity., 27, 1437-1446 (2003). https://doi.org/10.1038/sj.ijo.0802475
  7. S.H. Kim, Y.M. Lee, H.J. Jee and C.M. Nam, Effect of sibutramine on weight loss and blood pressure: A meta analysis of controlled trials. Obesity Res., 9, 599-603 (2003).
  8. N. Finer, Pharmacotherapy of obesity. Best. Pract. Res. Clin. Endocrinol. Metab., 16, 717-742 (2002). https://doi.org/10.1053/beem.2002.0231
  9. Z. Abolfathi, J. Couture, F. Vallee, M. Lebel, M. Tanguay and E. Masson, A pilot study toevaluate the pharmacokinetics of sibutramine in healthy subjects under fasting and fed conditions. J. Pharm. Pharmaceut. Sci., 7, 345-349 (2004).
  10. A.C. Williams and B.W. Barry, Penetration enhancers. Adv. Drug Deliver. Rev., 56, 603-618 (2004). https://doi.org/10.1016/j.addr.2003.10.025
  11. Y.-J. Cho and H.-K. Choi, Enhancement of percutaneous absorption of ketoprofen: Effect of vehicles and adhesive matrix. Int. J. Pharm., 169, 95-104 (1998). https://doi.org/10.1016/S0378-5173(98)00115-X
  12. I.D. Hind, J.E. Mangham, S.P. Ghani, R.E. Haddock, C.J. Garratt and R.W. Jones, Sibutramine Pharmacokinetics in young and elderly healthy subjects. Eur. J. Clin. Pharmacol., 54, 847-849 (1999). https://doi.org/10.1007/s002280050565
  13. R. Freynhfen, P. Busche, R. Savatowski, C. Konrad and S. Grond, Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: A prospective, multicenter pilot study in outpatients with chronic pain. J. Pain Symptom Mgmt., 30, 289-297 (2005). https://doi.org/10.1016/j.jpainsymman.2005.03.015
  14. N.T. Hai, J. Kim, E-S. Park and S-C. Chi, Formulation and biopharmaceutical evaluation of transdermal patch containing benztropine. Int. J. Pharm., 357, 55-60 (2008). https://doi.org/10.1016/j.ijpharm.2008.01.024
  15. S. Venkatraman and R. Gale, Skin adhesives and skin adhesion:1. Transdermal drug delivery systems. Biomaterials, 19, 1119-1136 (1998). https://doi.org/10.1016/S0142-9612(98)00020-9
  16. J.H. Kim, Y.J. Cho and H.K. Choi, Effect of vehicles and pressure sensitive adhesives on the permeation of tacrine across hairless mouse skin. Int. J. Pharm., 196, 105-113 (2000). https://doi.org/10.1016/S0378-5173(99)00449-4
  17. A.M. Wokovich, S. Prodduturi, W.H. Doub, A.S. Hussain and L.F. Buhse, Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute. Eur. J. Pharm. Biopharm., 64, 1-8 (2006). https://doi.org/10.1016/j.ejpb.2006.03.009
  18. H.A. Cheong and H.K. Choi, Enhanced percutaneous absorption of piroxicam via salt formation with ethanolamines. Pharm. Res., 19, 1375-1380 (2002). https://doi.org/10.1023/A:1020367212307
  19. H.M. Ki, and H.K. Choi, The effects of meloxicam/ethanolamine salt formation on percutaneous absorption of meloxicam. Arch. Pharm. Res., 30, 215-221 (2007). https://doi.org/10.1007/BF02977697
  20. K.A. Walters and J. Hadgraft, "Pharmaceutical skin penetration enhancement". Marcel Dekker, Inc.: New York, 113-138 (1993).
  21. E.S. Park, S.Y. Chang, M.K. Hahn and S.C. Chi, Enhancing effect of polyoxyethylene alkyl ethers on the skin permeation of ibuprofen. Int. J. Pharm., 209, 109-119 (2000). https://doi.org/10.1016/S0378-5173(00)00559-7
  22. F. Bucaretchi, E.M.D. Capitani, S.M. Mello, F. Lanaro, R.F. Barros, L.C.R. Fernandes and J.L.D. Costa, Serotonin syndrome following sibutramine poisoning in a child, with sequential quantification of sibutramine and its primary and secondary amine metabolites in plasma. Clin. Toxicol., 47, 598-601 (2009). https://doi.org/10.1080/15563650903018603